Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2004-N-0056] (formerly 2004N-0234)
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA) is publishing its annual guidance document agenda. This list is being published under FDA's good guidance practices (GGPs) regulations. It is intended to seek public comment on possible topics for future guidance document development or revisions of existing ones.
 DATES: Submit either electronic or written comments on this list and on any agency guidance document at any time.
 ADDRESSES: Submit electronic comments to 
                        *http://www.regulations.gov.*
                         Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.
 FOR FURTHER INFORMATION CONTACT: For general information regarding FDA's GGP policy contact: Lisa Helmanis, Office of Policy, Food and Drug Administration, 10903 New Hampshire Ave., WO32, rm. 3216, Silver Spring, MD 20993-0002, 301-796-9135. For information regarding specific topics or guidances, please see contact persons or specific offices listed in the table in the 
                        **SUPPLEMENTARY INFORMATION**
                         section of this document.


SUPPLEMENTARY INFORMATION: I. Background In the 
                    **Federal Register**
                     of September 19, 2000 (65 FR 56468), FDA issued its final rule on GGPs (21 CFR 10.115). GGPs are intended to ensure involvement of the public in the development of guidance documents and to enhance understanding of the availability, nature, and legal effect of such guidance documents. As part of FDA's effort to ensure meaningful interaction with the public regarding guidance documents, the Agency committed to publishing an annual guidance document agenda of possible guidance topics or documents for development or revision during the coming year. The Agency also committed to soliciting public input regarding these and additional ideas for new topics or revisions to existing guidance documents (65 FR 56468 at 56477; 21 CFR 10.115(f)(5)). The Agency is neither bound by this list of possible topics nor required to issue every guidance document on this list or precluded from issuing guidance documents not on the list set forth in this document. The following list of guidance topics or documents represents possible new topics or revisions to existing guidance documents that the Agency is considering. The Agency solicits comments on the topics listed in this document and also seeks additional ideas from the public. The guidance documents are organized by the issuing Center or Office within FDA, and in some cases are further grouped within the issuing Center or Office by topic categories. II. Center for Biologics Evaluation and Research (CBER)
                    ( print page 76012) Title/topic of guidance
ContactCATEGORY—BLOOD AND BLOOD COMPONENTS:
                             Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture 
                             Implementation of an Acceptable Abbreviated Donor History Questionnaire and Accompanying Materials for Use in Screening Frequent Donors of Blood and Blood Components 
                             Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaire and Accompanying Materials for Use in Screening Source Plasma Donors 
                             Use of Nucleic Acid Tests on Pooled and Individual Samples From Donors of Whole Blood and Blood Components (Including Recovered Plasma, Source Plasma and Source Leukocytes) to Adequately and Appropriately Reduce the Risk of Transmission of Hepatitis B Virus.
Office of Communication, Outreach and Development, Center for Biologics Evaluation and Research (HFM-40), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-1448, 301-827-1800.CATEGORY—CELLULAR, TISSUE, AND GENE THERAPY:
                             Preclinical Safety Assessment of Investigational Cellular, Gene Therapy, and Certain Related Products 
                             Characterization and Qualification of Cell Banks Used in the Production of Cellular and Gene Therapy Products 
                             Clinical Study Design for Early Phase Studies of Cellular and Gene Therapies.
Office of Communication, Outreach and Development, Center for Biologics Evaluation and Research (HFM-40), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-1448, 301-827-1800.CATEGORY—OTHER
                             Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information 
                             Bar Code Label Requirements—Question and Answer (Update for Vaccines).
Office of Communication, Outreach and Development, Center for Biologics Evaluation and Research (HFM-40), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-1448, 301-827-1800.
 III. Center for Drug Evaluation and Research (CDER) For information on the list of topics contact: Office of Training and Communications, Division of Drug Information, 10903 New Hampshire Ave., WO51, rm. 2201, Silver Spring, MD 20993, 301-796-3400, FAX: 301-847-8714, e-mail: 
                    *druginfo@fda.hhs.gov*. Category—Advertising Amendment of the Brief Summary
                Comparative Claims in Prescription Drug Promotion
                Direct to Consumer (DTC) Television Advertisements—Food and Drug Administration Amendments Act of 2007 (FDAAA) DTC Television Pre-Review Program
                Promotion of Prescription Drug Products Using Social Media Tools Category—Chemistry Chemistry, Manufacturing, and Controls (CMC)—Postmarketing Plan
                CMC Postapproval Changes Reportable in an Annual Report
                Comparability Protocols for Approved Drugs: CMC Information
                Standards Recognition
                Residual Drug in Transdermal Drug Delivery Systems Category—Clinical/Medical Clinical Development of Drugs for Irritable Bowel Syndrome
                Oncology Endpoints: Non-Small Cell Lung Cancer
                Qualification Process for Drug Development Tools
                Responsible Inclusion of Pregnant Women in Clinical Trials Category—Clinical Pharmacology Bioanalytical Methods Validation
                Clinical Pharmacogenomics: Study Design and Premarketing Evaluation
                Clinical Pharmacology Consideration for Therapeutics Proteins
                General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products
                Development of Extended Released Formulations Category—Clinical/Statistical Adaptive Trial Designs
                Multiple Endpoints
                Non-Inferiority Trials Category—Combination Products Drug Diagnostic Co-Development
                Development of Drugs in Combination Category—Current Good Manufacturing Practices (CGMPs)/Compliance Contract Manufacturing
                Control of Components
                Control of Highly Potent Compounds
                Expiration Dating of Unit-Dose Repackaged Drugs: Compliance Policy Guide
                Importation of Active Pharmaceutical Ingredients (API) for Use in Human Drugs
                Medical Gas, General CGMP
                Non-Penicillin Beta-Lactam Contamination
                Outsourcer Pharmacy Operations Compliance Policy Guide
                Pharmaceutical Component Quality Control
                Pharmaceutical Manufacturing Statistics
                Pre-Launch Activities Importation Request (PLAIR)
                Prevention and Control of Viral Contamination
                Validation of Air Separation Processes for Medical Gas Category—Drug Safety Information Best Practices for Conducting Pharmacovigilance Studies Using Electronic Healthcare Data
                Dear Healthcare Professional Letters
                Good Naming, Labeling, and Packaging Practices to Reduce Medication Errors Category—Electronic Submissions Electronic Submission of Summary Level Clinical Site Data for Data Integrity Review and Inspection Planning in New Drug Application (NDA) and Biologics License Application (BLA) Submissions
                Providing Regulatory Submissions in Electronic Format—Analysis Datasets and Documentation Category—Investigational New Drug Application (IND) Adverse Events: Collection and Reporting for Secondary Endpoints( print page 76013) Determining Whether Human Research Studies Can Be Conducted Without an IND IND Safety Reporting Category—Labeling Drug Names and Dosage Forms
                Pediatric Information: Incorporating into Human Prescription Drug and Biological Products Labeling Category—Procedural INDs prepared and submitted by Clinical Sponsor Investigators IV. Center for Devices and Radiological Health (CDRH) FDA has established a docket for CDRH, Docket No. FDA-2007-N-0270, for comments on any or all of the proposed fiscal year 2010 guidance documents. FDA invites interested persons to submit comments, draft language on the proposed topics, and/or suggestions for new or different guidance documents. FDA believes this docket is an important tool for receiving information from interested parties and for making information available to the public.  Guidance Related to FDAAA or General Premarket Issues 30-Day notices and 135-day Premarket Approval Application (PMA) Supplements Actions on 510(k) Submissions
                Annual Reports for PMAs
                Protocol Review Guidance for In Vitro Diagnostics (IVDs)
                Tracking Pediatric Device Approvals
                Premarket Notification Submissions for Medical Devices That Include Antimicrobial Agents Guidance on Postmarket and Compliance Issues Medical Device Reporting for Manufacturers
                Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act Electronic Registration and Listing
                Manufacturing Site Change Supplements: Content and Inspectional Considerations Quality Systems for Laboratory Developed Tests Device Specific Guidances Bacillus spp. Serological Reagents
                Clinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data
                Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data—Premarket Notification (510(k)) Submissions Coronary Drug Eluting Stents
                Dental Mouthguards
                Helicobacter Pylori
                Herpes Simplex Virus
                Impact-Resistant Lenses
                Invasive Portable Blood Glucose Monitoring Systems
                Ovarian Adnexal Mass Surgery Referral Index
                Percutaneous Transluminal Coronary Angioplasty Catheters
                Suction Apparatus Device Intended for Negative Pressure Wound Therapy
                Tissue Adhesive With Adjunct Wound Closure Device
                Topical Oxygen Chamber for Extremities
                Transcranial Magnetic Stimulation Systems
                Yersinia
                Zonisamide and Lamotrigine Assays Global Harmonization or Standards Related Guidances Application of IEC 60601-1 Third Edition in Premarket Applications
                Global Harmonization Task Force: Quality Management System; Process Validation Global Harmonization Task Force: Postmarket Surveillance; National Competent Authority Report Exchange Criteria and Report Form Crosscutting, Process, and Other Guidances Radio-Frequency Wireless Technology in Medical Devices
                Medical Device Appeals and Complaints: Guidance on Dispute Resolution
                Medical Devices Containing Materials From Animal Sources (Except IVDs) V. Center for Food Safety and Applied Nutrition (CFSAN) Title/topic of guidance
ContactNew Dietary Ingredient Notifications
Constance Hardy, CFSAN (HFS-810), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2375, 
                            *Constance.Hardy@fda.hhs.gov*.Fish and Fishery Products Hazards and Controls Guidance (Edition 4)
Thomas Latt, CFSAN (HFS-325), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1423, 
                            *Thomas.Latt@fda.hhs.gov*.Use of Dietary Guidance Statements
Blakeley Denkinger, CFSAN (HFS-830), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, (301-436-2176), 
                            *Blakeley.Denkinger@fda.hhs.gov*.Questions and Answers Regarding Food Allergens, Including the Food Allergen Labeling and Consumer Protection Act of 2004 (Edition 5)
Rhonda Kane, CFSAN (HFS-820), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1803, 
                            *Rhonda.Kane@fda.hhs.gov*.Processing of Acidified Foods
Michael Mignogna, CFSAN (HFS-302), Food and Drug Administration, 5100 Paint Branch Pkwy, College Park, MD 20740, 301-436-1515, 
                            *Michael.Mignogna@fda.hhs.gov*.Calorie Declaration
Vincent DeJesus, CFSAN (HFS-830), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1774, 
                            *Vincent.Dejesus@fda.hhs.gov*.Compliance Policy Guide Sec. 527.300 Dairy Products-Microbial Contaminants and Alkaline Phosphatase Activity (Compliance Policy Guide 7106.08)
Monica Metz, CFSAN (HFS-316), Food and Drug Administration, 5100 Paint Branch Pkwy, College Park, MD 20740, 301-436-2041, 
                            *Monica.Metz@fda.hhs.gov*.Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation
Nancy Bufano, CFSAN (HFS-315), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740., 301-436-1493, 
                            *Nancy.Bufano@fda.hhs.gov.*Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation
Nancy Bufano, CFSAN (HFS-315), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1493, 
                            *Nancy.Bufano@fda.hhs.gov*.( print page 76014)Positive Tests for Salmonella
Michael Kashtock, CFSAN (HFS-317), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2022, 
                            *Michael.Kashtock@fda.hhs.gov*.Compliance Policy Guide Sec. 550.050 Canned Ackee, Frozen Ackee, and Ackee Products—Adulteration With Hypoglycin A
Joyce Saltzman, CFSAN (HFS-317), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2041, 
                            *Joyce.Saltzman@fda.hhs.gov*.Assessing the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, Including Food Ingredients That are Color Additives
Annette McCarthy, CFSAN (HFS-205), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1057, 
                            *Annette.McCarthy@fda.hhs.gov*.Questions and Answers Regarding Voluntary Registration by Authorized Officials of Retail Food Establishments and by Vending Machine Operators Electing to be Subject to the Menu and Vending Machine Labeling Requirements Established by Section 4205 of the Patient Protection and Affordable Care Act
Felicia Billingslea, CFSAN (HFS-820), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2371, 
                            *Felicia.Billingslea@fda.hhs.gov*.Questions and Answers Regarding the Effect of Section 4205 of the Patient Protection and Affordable Care Act on State and Local Menu and Vending Machine Labeling Laws
Felicia Billingslea, CFSAN (HFS-820), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2371, 
                            *Felicia.Billingslea@fda.hhs.gov*.Safety of Nanoscale Materials in Cosmetic Products
Kapal Dewan, CFSAN (HFS-100), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1130, 
                            *Kapal.Dewan@fda.hhs.gov*.The Safety of Imported Traditional Pottery Intended for Use With Food and the Improper Use of the Terms “Lead Free,” and the Proper Identification of Ornamental and Decorative Ware
Michael Kashtock, CFSAN (HFS-317), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2022, 
                            *Michael.Kashtock@fda.hhs.gov*.
 VI. Center for Tobacco Products (CTP) Title/topic of guidance
ContactEnforcement Policy Concerning Rotational Warning Plans for Smokeless Tobacco Products
Office of Regulations, Center for Tobacco Products, Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-796-9250.Compliance With Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco to Protect Children and AdolescentsUse of “Light,” “Mild,” “Low,” or Similar Descriptors in the Label, Labeling, or Advertising of Tobacco Products“Harmful and Potentially Harmful Constituents” in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic ActTobacco Product Retailer Training ProgramCivil Money Penalties for Tobacco Retailers
 VII. Center for Veterinary Medicine (CVM) Title of Guidance
ContactDraft Guidance for Industry—Safe Animal Feeding
Phares Okelo, Center for Veterinary Medicine (HFV-226), Food and Drug Administration, 7519 Standish Pl., MPN-4, rm. 2661, Rockville, MD 20855, 240-453-6862,
                            *phares.okelo@fda.hhs.gov.*Draft Compliance Policy Guide—Glucosamine/Chondroitin Animal Products
Paul Bachman, Center for Veterinary Medicine (HFV-230), Food and Drug Administration, 7519 Standish Pl., MPN-4, rm. 143, Rockville, MD 20855, 240-276-9225, 
                            *paul.bachman@fda.hhs.gov.*Final Guidance for Industry—Comparability Protocols
Dennis Bensley, Center for Veterinary Medicine (HFV-140), Food and Drug Administration, 7500 Standish Pl., MPN-2, rm. E334, Rockville, MD 20855, 240-276-8268, 
                            *dennis.bensley@fda.hhs.gov.*Draft Guidance for Industry—Fermentation Derived Intermediates, Drug Substances, and Related Drug Products for Veterinary Medicinal Use—Chemistry, Manufacturing, and Controls Information
Michael Popek, Center for Veterinary Medicine (HFV-144), Food and Drug Administration, 7500 Standish Pl., MPN-2, rm. E335, Rockville, MD 20855, 240-276-8269, 
                            *michael.popek@fda.hhs.gov.*Final Guidance for Industry—Drug Substance Chemistry, Manufacturing, and Controls Information
Dennis Bensley, Center for Veterinary Medicine (HFV-140), Food and Drug Administration, 7500 Standish Pl., MPN-2, rm. E334, Rockville, MD 20855, 240-276-8268, 
                            *dennis.bensley@fda.hhs.gov.*Draft Guidance for Industry—Active Controls in Studies to Demonstrate Effectiveness of a New Animal Drug for Use in Companion Animals
Urvi Desai, Center for Veterinary Medicine (HFV-110), Food and Drug Administration, 7520 Standish Pl., MPN-1, rm. 203, Rockville, MD 20855, 240-276-8297, 
                            *urvi.desai@fda.hhs.gov.*Draft Guidance for Industry—Judicious Use of Antimicrobial Drugs in Food-Producing Animals
William Flynn, Center for Veterinary Medicine (HFV-1), Food and Drug Administration, 7519 Standish Pl. MPN-4, rm. 173, Rockville, MD 20855, 240-276-9084, 
                            *William.flynn@fda.hhs.gov.*( print page 76015)Draft Guidance for Industry—Active Controls in Studies to Demonstrate the Effectiveness of a New Drug for Use in Companion Animals
Lisa Troutman, Center for Veterinary Medicine (HFV-116), Food and Drug Administration, 7500 Standish Pl., MPN-2, rm. N319, Rockville, MD 20855, 240-276-8322, 
                            *lisa.troutman@fda.hhs.gov.*Residual Solvents in Animal Drug Products; Questions and Answers
Sudesh Kamath, Center for Veterinary Medicine (HFV-145), Food and Drug Administration, 7500 Standish Pl., MPN-2, rm. E365, Rockville, MD 20855, 240-276-8260, 
                            *sudesh.kamath@fda.hhs.gov.*Draft Guidance for Industry—Updating Labeling of Certain Antimicrobial New Animal Drug Products for Use in the Feed or Water of Food-Producing Animals
William Flynn, Center for Veterinary Medicine (HFV-1), Food and Drug Administration, 7519 Standish Pl., MPN-4, rm. 173, Rockville, MD 20855, 240-276-9084, 
                            *William.flynn@fda.hhs.gov.*Final Guidance for Industry—Bracketing and Matrixing Designs for Stability Testing of New Veterinary Drug Substances and Medicinal Products, VICH GL-45
Dennis Bensley, Center for Veterinary Medicine (HFV-140), Food and Drug Administration, 7500 Standish Pl., MPN-2, rm. E334, Rockville, MD 20855, 240-276-8268, 
                            *dennis.bensley@fda.hhs.gov.*Revised Draft Guidance for Industry—Impurities: Residual Solvents In New Veterinary Medicinal Products, Active Substances and Excipients, VICH GL18(R)
Mai, Huynh, Center for Veterinary Medicine, (HFV-142), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-276-8273, 
                            *Mai.huynh@fda.hhs.gov.*Draft Guidance for Industry—Evaluating the Effectiveness of Anticoccidial Drugs in Food-Producing Animals
Emily R. Smith, (HFV-135), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-276-8344, e-mail: 
                            *emily.smith2@fda.hhs.gov.*Draft Guidance for Industry—Protocol Submissions for the Division of Therapeutic Drugs for Non-Food Animals the Division of Production Drugs, and the Division of Therapeutic Drugs for Food Animals
Angela Clarke, Center for Veterinary Medicine (HFV-105), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-276-8318; e-mail: 
                            *angela.clarke@fda.hhs.gov.*
 VIII. Office of the Commissioner Guidance title/TOPIC
OC Contact• Classification of products as biological products, devices, and drugs
John Weiner, Office of Combination Products, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993 301-796-8941.• Interpretation of the term “chemical action' in definition of device under section 201(h) of the Federal Food, Drug, and Cosmetic Act
Do.• Types of submissions for postapproval changes to combination products
Do.• Information Sheet Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors—FDA Inspections of Clinical Investigators
                             Describes FDA's inspectional process when the agency inspects the site of an investigator who is conducting a clinical study regulated by FDA
Bridget Foltz, Office of Good Clinical Practices, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, 301-796-8348.• Draft Information Sheet Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors—A Guide to Informed Consent
                             Describes in detail basic and additional elements of informed consent and includes topics such as review of patient records, children as subjects, and subject participation in more than one study
Sara Goldkind (301-796-8342), Marsha Melvin (301-796-8345), Office of Good Clinical Practices, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993.• Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors—Exception From Informed Consent Requirements for Emergency Research
                             This final guidance is intended to assist sponsors, clinical investigators, and IRBs in the development, conduct, and oversight of research involving FDA-regulated products (e.g., drugs, biological products, devices) in emergency settings when an exception from the informed consent requirements is requested under 21 CFR 50.24. In particular, the guidance clarifies FDA's expectations related to planning and conducting community consultation and public disclosure activities, and the establishment of informed consent procedures to be used when feasible
Sara Goldkind, Office of Good Clinical Practices, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993, 301-796-8348.
 Dated: December 1, 2010. Leslie Kux, Acting Assistant Commissioner for Policy.


[FR Doc. 2010-30623 Filed 12-6-10; 8:45 am] BILLING CODE 4160-01-P